Melanoma News and Research

Latest Melanoma News and Research

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Columbia University will award the 2014 Louisa Gross Horwitz Prize to James P. Allison, PhD, of the University of Texas MD Anderson Cancer Center, for his work on understanding the process of T-cell activation and for developing therapies that harness the immune system to fight cancer.

3 Oct 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

GSK today announced updated results for Tafinlar (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma.

30 Sep 2014

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.

30 Sep 2014

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Combination therapy achieves greater progression-free survival, response rates in melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

30 Sep 2014

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

29 Sep 2014

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Arisaph Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on discovery and development of novel therapies for cardiometabolic diseases and cancer, announced today that it has been awarded a phase II Small Business Technology Transfer (STTR) grant and a supplemental phase I grant, both from the National Cancer Institute of the National Institutes of Health.

29 Sep 2014

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine to coincide with a presentation at the European Society for Medical Oncology meeting, an international research team reports that crizotinib treatment led to significant tumor shrinkage in 36 of 50 study participants and suppressed tumor growth in another 9.

29 Sep 2014

BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

A protein implicated in several cancers appears to play a pivotal role in keeping stem cells in an immature "pluripotent" state, according to a new study by NYU Langone Medical Center scientists.

26 Sep 2014

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

EKF, announces that it has entered into a two year research collaboration with Massachusetts General Hospital.

From EKF Diagnostics 23 Sep 2014

Longer telomeres increase melanoma risk

A leading Dartmouth researcher, working with The Melanoma Genetics Consortium, GenoMEL, an international research consortium, co-authored a paper published today in the Journal of the National Cancer Institute that proves longer telomeres increase the risk of melanoma.

21 Sep 2014

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy.

19 Sep 2014

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers.

18 Sep 2014

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

With a presence in over 500 clinics around the world, Xstrahl have drawn upon their vast clinical expertise to develop a revolutionary system that has been specifically designed for the treatment superficial skin cancers and skin conditions.

From Xstrahl 18 Sep 2014

New approach to imaging metastatic tumors

Bioluminescence, nanoparticles, gene manipulation - these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors.

18 Sep 2014

Study uncovers new genetic risk factor for deadly skin cancer

Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma - the deadliest form of skin cancer - according to new research from the University of Leeds.

18 Sep 2014

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of the Epicure project, which has just received financial backing from France’s national research agency, the ANR [Agence Nationale pour la Recherche].

17 Sep 2014

Soldiers deployed to sunny climates face increased risk of skin cancer

Soldiers deployed to tropical and sunny climates are coming home with increased risk factors for a threat far from the battlefield: skin cancer.

17 Sep 2014

Melanoma News and Research

Latest Melanoma News and Research

MD Anderson's James P. Allison to receive 2014 Louisa Gross Horwitz Prize for work on immunotherapy

Combination treatment prevents disease progression in patients with advanced melanoma

GSK reports 45% survival rate in phase III study of Tafinlar in BRAF V600E mutant metastatic melanoma

PD-L1 protein could be a potential immunotherapy target for malignant pleural mesothelioma

Nivolumab drug achieves superior response rates in previously-treated advanced melanoma patients

Combination therapy achieves greater progression-free survival, response rates in melanoma

Targeted combination drug therapy can extend life, halt disease in metastatic melanoma patients

Arisaph Pharmaceuticals receives STTR grants to develop cancer drug candidates

Dabrafenib shows significant anti-tumour activity in BRAF V600E mutant non-small cell lung cancer

Crizotinib drug effectively halts growth of ROS1-positive lung tumors

BRD4 protein appears to play key role in keeping stem cells in immature "pluripotent" state

Circulating tumour cell clinical research collaboration announced between EKF Diagnostics and Massachusetts General Hospital

Longer telomeres increase melanoma risk

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Photoelectric therapy for non-melanoma skin cancer developed by Xstrahl

New approach to imaging metastatic tumors

Study uncovers new genetic risk factor for deadly skin cancer

Curie-Cancer, Inventiva launch Epicure project that aims to develop epigenetic targets for cancer

Soldiers deployed to sunny climates face increased risk of skin cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in